In 2002 a 23-yr-old female giant panda (Ailuropoda melanoleuca) presented with left hind limb lameness presumably due to osteoarthritis. For the next five years, arthritic episodes were managed with the nonsteroidal anti-inflammatory drug (NSAID) carprofen at 2 mg/kg p.o. s.i.d., then reduced to 1 mg/kg p.o. s.i.d. and withdrawn. Radiographs revealed osteoarthritis in various joints and lumbar spondylosis. In 2007 glucosamine and chondroitin at 1.65 g p.o. b.i.d. and a polyunsaturated fatty acid at 1 capsule p.o. s.i.d. By 2008, arthritic episodes were becoming more difficult to successfully manage and higher doses and longer durations of treatment with carprofen were needed (2 mg/kg p.o. b.i.d.) and by August 2009 episodic treatment was no longer successful so the carprofen was continued indefinitely at 1 mg/kg p.o. s.i.d. In November 2009 carprofen was increased to 2 mg/kg p.o. b.i.d. An NMDA antagonist amantadine sulphate was trialed and after 10 days at 200 mg p.o. s.i.d. the clinical signs resolved. Since then it has been maintained on carprofen at 1 mg/kg p.o. b.i.d., amantadine sulphate 200 mg p.o. s.i.d. and the neutraceuticals as above with no further relapses of arthritic pain.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.